Milestone Pharmaceuticals inc (MIST)
Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
News
Etripamil: A Promising Therapeutic Approach for Paroxysmal Supraventricular Tachycardia
Milestone Pharmaceuticals Inc. Sees Unwavering Revenue as they Dive into the Third Quarter of 2023
announced Revenue of $1.5 millions, in the financial period ending September 30 2022
released Revenue of $1.5 millions, in the July to September 30 2022